Semax and Mexidol both reduce amnesia and hypoxia but require distinct dosing strategies

Hypoxia-induced neuronal damage and amnesia represent overlapping clinical challenges in cerebrovascular and cognitive medicine, where standard nootropics like piracetam offer modest, nonspecific benefit. Acute hypobaric, hemic, and histotoxic hypoxia models each stress distinct oxygen-delivery pathways, and no single agent covers all axes reliably. Semax, an ACTH(4-7) analogue peptide, is studied for neuroprotective and nootropic potential via modulation of central neuroregulatory pathways, while mexidol (2-ethyl-6-methyl-3-hydroxypyridine succinate) targets mitochondrial oxidative phosphorylation. The gap this work addresses is whether either agent outperforms classical nootropes and whether dosing regimen — single vs. repeated course — materially changes efficacy across these overlapping endpoints.

Experiments used mice exposed to altitude chamber and hermetic chamber tests for acute hypobaric hypoxia, plus hemic and histotoxic hypoxia models. Both mexidol (75–100 mg/kg) and semax (0.05–0.1 mg/kg) were administered either as a single dose or as a 6-day preventive course. Antiamnesic efficacy was tested across multiple amnesia models in mice, with piracetam and oxyracetam as reference nootrope controls. Hippocampal slice electrophysiology in rats assessed ortho- and antidromic population spike responses of CA1 pyramidal neurons. Mitochondrial oxygen consumption in rat brain tissue was measured to probe metabolic mechanism.

Single administration of mexidol at 100 mg/kg and semax at 0.05 mg/kg produced antihypoxic effects in altitude and hermetic chamber models, while lower single doses were ineffective. After a 6-day preventive course, both compounds achieved significant antihypoxic effects at mexidol 75 mg/kg/day and semax 0.1 mg/kg/day — doses that failed as single administrations, indicating course priming is functionally necessary at those levels.

Neither mexidol nor semax produced antihypoxic effects on acute hemic or histotoxic hypoxia models under any single-dose condition tested.

On amnesia models (excluding maximal electroshock), both compounds showed marked antiamnesic effects comparable to piracetam and oxyracetam. Mexidol showed a linear dose-effect relationship for both antihypoxic and antiamnesic endpoints, whereas semax exhibited a bell-shaped, reversible dose-effect curve, meaning efficacy peaks and declines at higher doses. In hippocampal slice preparations, both drugs inhibited ortho- and antidromic CA1 population response spikes. Mexidol, but not semax, increased oxygen consumption in rat brain mitochondria with a linear relationship across 1–5 mM concentration, suggesting a direct mitochondrial energetic mechanism distinct from semax's mode of action.

Written by TitrateLab, separately from the study summarized above.